KROS Earnings Date: Nov 4, 2026 (Estimated) — Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is KROS's next earnings date?
Keros Therapeutics, Inc. (KROS) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.96 on revenue of $14.8M.
How did KROS do in its last earnings report?
In its most recent report on Aug 3, 2026 (Q2 2026), Keros Therapeutics, Inc. posted EPS of -$1.45 versus the -$1.24 estimate, a miss of 16.9%. Revenue was $0 against a $635,000 estimate. The stock's 1-day post-earnings move was +1.4%.
How much does KROS stock move after earnings?
KROS beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.9% (up or down) in the day after earnings.
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | -1.24 | -1.45 | -16.94% | $0 | ❌ Miss | +1.38% | +5.74% | +9.50% |
| 2026-05-14 | Q1 2026 | -0.92 | -1.21 | -31.52% | $367,000 | ❌ Miss | -8.34% | -8.42% | -15.35% |
| 2026-03-04 | Q4 2025 | -0.47 | -0.86 | -82.98% | $385,000 | ❌ Miss | -14.96% | -18.16% | -12.85% |
| 2025-11-05 | Q3 2025 | -1.00 | -0.18 | +82.00% | $14.3M | ✅ Beat | +3.32% | +11.63% | +38.59% |
| 2025-08-06 | Q2 2025 | -1.13 | -0.76 | +32.74% | $18.2M | ✅ Beat | -7.29% | -3.12% | +8.19% |
| 2025-02-26 | Q4 2024 | -0.96 | -1.14 | -18.75% | $3.0M | ❌ Miss | +0.64% | +6.67% | +0.46% |
| 2024-11-06 | Q3 2024 | -1.27 | -1.41 | -11.02% | $388,000 | ❌ Miss | +1.08% | -5.09% | +5.34% |
| 2024-08-07 | Q2 2024 | -1.23 | -1.25 | -1.63% | $37,000 | ❌ Miss | -2.18% | -4.47% | +15.66% |
Showing last 8 quarters.